MEDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MEDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Trxade Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $8.422. Trxade Health's 10-Year median PS Ratio is 4.4621. Therefore, the Median PS Value for today is $37.58.
As of today (2024-04-28), Trxade Health's share price is $6.31. Trxade Health's Median PS Value is $37.58. Therefore, Trxade Health's Price to Median PS Value for today is 0.17.
The historical rank and industry rank for Trxade Health's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Trxade Health was 0.17. The lowest was 0.14. And the median was 0.14.
The historical data trend for Trxade Health's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trxade Health Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | 37.58 |
Trxade Health Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Median PS Value | Get a 7-Day Free Trial | - | 76.43 | 62.39 | 49.68 | 37.58 |
For the Pharmaceutical Retailers subindustry, Trxade Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Trxade Health's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Trxade Health's Price-to-Median-PS-Value falls into.
Trxade Health's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 8.422 | * | 4.4621 | |
= | 37.58 |
10-Year Median PS Ratio is 4.4621.
Trxade Health's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.422.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trxade Health (NAS:MEDS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Trxade Health's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 6.31 | / | 37.58 | |
= | 0.17 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Trxade Health's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
A. Jeffrey Newell | director | 645 CAMP DIXIE RD, PASCOAG RI 02859 |
Donald G. Fell | director | 17537 DARBY LANE, LUTZ FL 33558 |
Janet Huffman | officer: CFO, PAO, PFO | 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232 |
Michael L Peterson | director | 17 CANARY COURT, DANVILLE CA 94526 |
Christine L. Jennings | director | 3840 LAND O' LAKES BLVD., LAND O' LAKES FL 34639 |
Prashant Patel | director, 10 percent owner, officer: President | 17537 DARBY LANE, LUTZ FL 33558 |
Pamela Tenaerts | director | PO BOX 15012, SARASOTA FL 34277 |
Gary Augusta | director | 700 NORTH BRAND BLVD., SUITE 1400, GLENDALE CA 91203 |
Howard A. Doss | officer: CFO | 17537 DARBY LANE, LUTZ FL 90067 |
Surendra K Ajjarapu | director, 10 percent owner, officer: CEO | 8604 BUTTON BUSH CT, TAMPA FL 33647 |
Donald V. Almeida | director | 1115 GUNN HIGHWAY, SUITE 202, ODESSA FL 33556 |
Charles L Pope | director | 4902 EISENHOWER BOULEVARD, TAMPA FL 33634 |
Sandhya Ajjarapu | 10 percent owner | 17537 DARBY LANE, LUTZ FL 33558 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 12-06-2022
By GlobeNewswire • 07-14-2023
By ACCESSWIRE ACCESSWIRE • 08-16-2022
By Marketwired • 09-07-2023
By Marketwired • 07-31-2023
By ACCESSWIRE ACCESSWIRE • 10-24-2022
By GlobeNewswire • 06-23-2023
By ACCESSWIRE ACCESSWIRE • 08-24-2022
By Value_Insider Value_Insider • 10-25-2022
By Marketwired • 06-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.